Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567198 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL10018240 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL15086086 | 0.76 | CES2 (0.43) | ALDH1A1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL8413968 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL7787413 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KMT2ATDP1SMN1; SMN2HPGD | |
| SCHEMBL13663403 | 0.76 | CES2 (0.43) | ALDH1A1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL29290139 | 0.72 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL5172196 | 0.71 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9512111 | 0.71 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9512116 | 0.71 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3992/4885MEN1 4649/4885KMT2A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.